









Markets
/
Stocks
/
nasdaq-clpt
/

Clearpoint Neuro Inc

CLPT

11.350USD

+0.690+6.47%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

322.61MMarket Cap

LossP/E TTM



Clearpoint Neuro Inc

11.350

+0.690+6.47%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

94 / 207

Overall Ranking

243 / 4723

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

29.000

Target Price

+172.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 52.74% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 31.39M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 15.08.

Overvalued

The company’s latest PE is -13.32, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 12.82M shares, increasing 2.66% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.48M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.61.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.77, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 9.21M, representing a year-over-year increase of 17.27%, while its net profit experienced a year-over-year increase of 32.42%.

Score

Industry at a Glance

Previous score

7.08

Change

0.69



Financials

8.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.68

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.84

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.28

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -13.32, which is 10.58% below the recent high of -14.73 and -42.63% above the recent low of -19.00.

Score

Industry at a Glance

Previous score

2.00

Change

-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 94/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Clearpoint Neuro Inc is 29.00, with a high of 30.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

29.000

Target Price

+172.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Clearpoint Neuro Inc

CLPT

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.78, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 11.41 and the support level at 9.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.109

Neutral

RSI(14)

57.511

Neutral

STOCH(KDJ)(9,3,3)

61.959

Buy

ATR(14)

0.569

High Vlolatility

CCI(14)

125.439

Buy

Williams %R

9.174

Overbought

TRIX(12,20)

-0.036

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

10.724

Buy

MA10

10.817

Buy

MA20

10.682

Buy

MA50

10.891

Buy

MA100

11.752

Sell

MA200

13.269

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 45.36%, representing a quarter-over-quarter increase of 6.07%. The largest institutional shareholder is The Vanguard, holding a total of 1.48M shares, representing 5.19% of shares outstanding, with 14.80% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

368.02K

-0.05%

The Vanguard Group, Inc.

Star Investors

1.28M

+2.85%

Bigger Capital Funds, LP

422.40K

-61.99%

PTC Therapeutics Inc

894.58K

Geode Capital Management, L.L.C.

301.37K

+6.15%

District 2 Capital LP

1.13M

+170.85%

Bigger (Michael)

378.69K

+5.58%

Brown Advisory

331.10K

-0.69%

Essex Investment Management Company, LLC

327.46K

-19.90%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.51, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.